From: A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
Anti-HBs titer (mIU/ml)
Group 1 (N = 113) Hexavac® n (%)
Group 2 (N = 124) Infanrix Hexa® n (%)
p-value
RR (95%CI)
< 10
35 (31.0)
5 (4.0)
< 0.0001*
7.7 (3.1 – 18.9)
10 – 99
47 (41.6)
22 (17.8)
< 0.0001**
3.3 (2.1 – 4.9)
≥ 100
31 (27.4)
97 (78.2)
-